A Phase I Study of CX5461

Trial Profile

A Phase I Study of CX5461

Phase of Trial: Phase I

Latest Information Update: 06 Aug 2018

At a glance

  • Drugs CX 5461 (Primary)
  • Indications Advanced breast cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Jul 2018 Phase has been changed from I/II to phase I, hence planned number has reduced and primary endpoint has been removed for phase II. Hence trial focus TU has been removed.
    • 25 Jul 2018 Planned number of patients changed from 98 to 60.
    • 14 May 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top